Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Remdesivir granted early access in the UK by MHRA for COVID-19 treatment.- Gilead Sciences

Written by | 29 May 2020 | COVID-19

Remdesivir has been granted a special early access status in the UK, which will allow patients hospitalized with COVID-19 to receive the antiviral treatment.The public assessment report issued by the Medicines and Healthcare products Regulatory Agency (MHRA) cites trial data which shows remdesivir reduced the time of recovery from 15 days to 11 days in patients with severe COVID-19 These data are the same data from an NIH-led study which led the FDA to grant remdesivir emergency use approval (EUA) on 2 May.

A new study published in the New England Journal of Medicine (NEJM) on 22 May 2020 added to these data, confirming some of earlier trial’s signs of benefits, but showing no benefits for the most critically ill and intubated patients.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.